Geoffrey Greene

Research Summary
The overall objective of my research is to determine the molecular distinctions between estrogen, androgen, progestin, and glucocorticoid agonism and antagonism in hormone-dependent tissues and cancers and to use this information to identify, develop and characterize novel compounds that can be used as breast and prostate cancer chemopreventatives and chemotherapeutics. I have considerable experience and expertise with the identification and characterization of novel compounds (SERMs, SERDs, SPRMs) that selectively target the two estrogen receptors, ERalpha and ERbeta, and progesterone receptor (PR). More recently, my lab has also begun to focus on AR and GR therapeutics. One of our specific goals is to test and develop known and novel SERMs/SARMS/SPRMs/SGRMs for their ability to selectively alter ER/PR, ER/AR and ER/GR recruitment of coregulator subsets that reflect differential responses to these ligands. My lab has solved multiple crystal structures of the ERalpha and ERbeta ligand-binding domains bound to diverse SERMs, which has contributed significantly to our understanding of the structural basis for agonist and antagonist interactions with both ERs, and how the two ER subtypes differentially discriminate among ligands. We have also solved the crystal structure of AR LBD bound to DHT and ERalpha LBD bound to several stapled peptides that bind to and inhibit the transcriptional activating AF2 function of ERalpha. Structural studies are being expanded to include cryoEM analysis of receptor/DNA/coregulator complexes. In addition, we are actively characterizing ERalpha somatic mutations that have been observed in endocrine therapy resistant metastatic breast cancers, with the goal of targeting these mutant ERs with next generation SERMs/SERDs. More recently, we have been studying the role of NCoA3 and other nuclear receptor coregulators as mediators of survival, invasion and metastasis in TNBC. We use and are developing both cell-derived explant and PDX models as platforms for studying both ER+ and ER- breast cancer progression and treatment with existing as well as novel therapy combinations that target multiple steroid receptors and their coregulators. I have a strong background in understanding and modulating breast cancer genesis, progression, treatment and prevention.
Breast Cancer, Hormone Receptors, Nuclear, Estrogen Receptors, Progesterone Receptor, Androgen Receptor, Glucocorticoid Receptor, SERMs, SERDS, Prostate Cancer, PDX models, Metastasis, organoids
  • The College of Wooster, Wooster, Ohio, B.A. Chemistry 1969
  • Northwestern University, Evanston, IL, Ph.D. Chemistry 1974
  • The University of Chicago, Chicago, IL, postdoc Biochemical Endocrinology 1977
Biosciences Graduate Program Association
Awards & Honors
  • 1988 - Ernst Oppenheimer Award The Endocrine Society
  • 1997 - Tartikoff-Semel Award Revlon/UCLA Women’s Cancer Research Program
  • 2003 - Virginia and D. K. Ludwig Professor for Cancer Research Ludwig Institute for Cancer Research
  • 2006 - NAMS/Wyeth Pharmaceutical SERMs award North American Menopausal Society
  • 2009 - Susan G. Komen for the Cure Brinker Award for Scientific Distinction Susan G. Komen Foundation
  • 2017 - AAAS Fellow American Association for the Advancement of Science
  1. Pal P, Millner A, Semina SE, Huggins RJ, Running L, Aga DS, Tonetti DA, Schiff R, Greene GL, Atilla-Gokcumen GE, Frasor J. Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers (Basel). 2022 May 12; 14(10). View in: PubMed

  2. Hosfield DJ, Weber S, Li NS, Suavage M, Joiner CF, Hancock GR, Sullivan EA, Ndukwe E, Han R, Cush S, Lainé M, Mader SC, Greene GL, Fanning SW. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 May 16; 11. View in: PubMed

  3. Semina SE, Pal P, Kansara NS, Huggins RJ, Alarid ET, Greene GL, Frasor J. Selective pressure of endocrine therapy activates the integrated stress response through NF?B signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res. 2022 Mar 09; 24(1):19. View in: PubMed

  4. Boudreau MW, Duraki D, Wang L, Mao C, Kim JE, Henn MA, Tang B, Fanning SW, Kiefer J, Tarasow TM, Bruckheimer EM, Moreno R, Mousses S, Greene GL, Roy EJ, Park BH, Fan TM, Nelson ER, Hergenrother PJ, Shapiro DJ. A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Sci Transl Med. 2021 07 21; 13(603). View in: PubMed

  5. Mayne CG, Toy W, Carlson KE, Bhatt T, Fanning SW, Greene GL, Katzenellenbogen BS, Chandarlapaty S, Katzenellenbogen JA, Tajkhorshid E. Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Mol Cancer Res. 2021 09; 19(9):1559-1570. View in: PubMed

  6. Lainé M, Fanning SW, Chang YF, Green B, Greene ME, Komm B, Kurleto JD, Phung L, Greene GL. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54. View in: PubMed

  7. Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang YF, Blank A, Reardon CA, Kenny HA, Vaisar T, Lengyel E, Greene G, Becker L. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21. View in: PubMed

  8. Gruener RF, Ling A, Chang YF, Morrison G, Geeleher P, Greene GL, Huang RS. Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling. Cancers (Basel). 2021 Feb 20; 13(4). View in: PubMed

  9. Abderrahman B, Maximov PY, Curpan RF, Fanning SW, Hanspal JS, Fan P, Foulds CE, Chen Y, Malovannaya A, Jain A, Xiong R, Greene GL, Tonetti DA, Thatcher GRJ, Jordan VC. Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Mol Cancer Ther. 2021 01; 20(1):11-25. View in: PubMed

  10. Maximov PY, Abderrahman B, Hawsawi YM, Chen Y, Foulds CE, Jain A, Malovannaya A, Fan P, Curpan RF, Han R, Fanning SW, Broom BM, Quintana Rincon DM, Greenland JA, Greene GL, Jordan VC. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37. View in: PubMed

  11. Kastrati I, Joosten SEP, Semina SE, Alejo LH, Brovkovych SD, Stender JD, Horlings HM, Kok M, Alarid ET, Greene GL, Linn SC, Zwart W, Frasor J. The NF-?B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res. 2020 07; 18(7):1018-1027. View in: PubMed

  12. Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, Jiang T, Broadwater G, Hyslop T, Hall A, Laine M, Phung L, Greene GL, Martin LA, Pancholi S, Dowsett M, Detre S, Marks JR, Crawford GE, Brown M, Norris JD, Chang CY, McDonnell DP. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019 10 22; 29(4):889-903.e10. View in: PubMed

  13. Montgomery JE, Donnelly JA, Fanning SW, Speltz TE, Shangguan X, Coukos JS, Greene GL, Moellering RE. Versatile Peptide Macrocyclization with Diels-Alder Cycloadditions. J Am Chem Soc. 2019 10 16; 141(41):16374-16381. View in: PubMed

  14. Fanning SW, Greene GL. Next-Generation ERa Inhibitors for Endocrine-Resistant ER+ Breast Cancer. Endocrinology. 2019 04 01; 160(4):759-769. View in: PubMed

  15. Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7. View in: PubMed

  16. Sharma A, Toy W, Guillen VS, Sharma N, Min J, Carlson KE, Mayne CG, Lin S, Sabio M, Greene G, Katzenellenbogen BS, Chandarlapaty S, Katzenellenbogen JA. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chem Biol. 2018 12 21; 13(12):3374-3384. View in: PubMed

  17. Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S. Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018 Oct; 18(10):662. View in: PubMed

  18. Fanning SW, Hodges-Gallagher L, Myles DC, Sun R, Fowler CE, Plant IN, Green BD, Harmon CL, Greene GL, Kushner PJ. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018 06 18; 9(1):2368. View in: PubMed

  19. Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF, Rincon DMQ, Greenland JA, Rajan SS, Greene GL, Jordan VC. Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol. 2018 08; 94(2):812-822. View in: PubMed

  20. Speltz TE, Mayne CG, Fanning SW, Siddiqui Z, Tajkhorshid E, Greene GL, Moore TW. A "cross-stitched" peptide with improved helicity and proteolytic stability. Org Biomol Chem. 2018 05 23; 16(20):3702-3706. View in: PubMed

  21. Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018 06; 18(6):377-388. View in: PubMed

  22. West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446. View in: PubMed

  23. Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL. Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. Oncotarget. 2018 Jan 12; 9(4):4282-4300. View in: PubMed

  24. House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983. View in: PubMed

  25. Walter KR, Goodman ML, Singhal H, Hall JA, Li T, Holloran SM, Trinca GM, Gibson KA, Jin VX, Greene GL, Hagan CR. Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer. Mol Cancer Res. 2017 10; 15(10):1331-1340. View in: PubMed

  26. Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017 03; 7(3):277-287. View in: PubMed

  27. Bourgo RJ, Singhal H, Greene GL. Capture of associated targets on chromatin links long-distance chromatin looping to transcriptional coordination. Nat Commun. 2016 09 16; 7:12893. View in: PubMed

  28. Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv. 2016 06; 2(6):e1501924. View in: PubMed

  29. Speltz TE, Fanning SW, Mayne CG, Fowler C, Tajkhorshid E, Greene GL, Moore TW. Stapled Peptides with ?-Methylated Hydrocarbon Chains for the Estrogen Receptor/Coactivator Interaction. Angew Chem Int Ed Engl. 2016 Mar 18; 55(13):4252-5. View in: PubMed

  30. Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016 Feb 02; 5. View in: PubMed

  31. Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52. View in: PubMed

  32. Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A, Drougard A, Rajan S, Laine M, Milon A, Muller I, Henrion D, Adlanmerini M, Valéra MC, Gompel A, Gerard C, Péqueux C, Mestdagt M, Raymond-Letron I, Knauf C, Ferriere F, Valet P, Gourdy P, Katzenellenbogen BS, Katzenellenbogen JA, Lenfant F, Greene GL, Foidart JM, Arnal JF. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor a modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014 Oct; 6(10):1328-46. View in: PubMed

  33. Greene GL. In memoriam: Elwood Jensen (1920-2012). Endocr Rev. 2013 Dec; 34(6):761-3. View in: PubMed

  34. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec; 45(12):1439-45. View in: PubMed

  35. O'Leary KA, Jallow F, Rugowski DE, Sullivan R, Sinkevicius KW, Greene GL, Schuler LA. Prolactin activates ERa in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology. 2013 Dec; 154(12):4483-92. View in: PubMed

  36. Greene GL. In memoriam: Elwood Jensen (1920-2012). Endocrinology. 2013 Oct; 154(10):3489-91. View in: PubMed

  37. Le TP, Sun M, Luo X, Kraus WL, Greene GL. Mapping ERß genomic binding sites reveals unique genomic features and identifies EBF1 as an ERß interactor. PLoS One. 2013; 8(8):e71355. View in: PubMed

  38. Huang W, Greene GL, Ravikumar KM, Yang S. Cross-talk between the ligand- and DNA-binding domains of estrogen receptor. Proteins. 2013 Nov; 81(11):1900-9. View in: PubMed

  39. Chapa J, Bourgo RJ, Greene GL, Kulkarni S, An G. Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS One. 2013; 8(5):e64091. View in: PubMed

  40. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499. View in: PubMed

  41. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393. View in: PubMed

  42. Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013 Jan; 137(2):373-82. View in: PubMed

  43. Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel E. The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41. View in: PubMed

  44. Liu H, Bockhorn J, Dalton R, Chang YF, Qian D, Zitzow LA, Clarke MF, Greene GL. Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting. J Virol Methods. 2011 May; 173(2):266-70. View in: PubMed

  45. Walker MP, Zhang M, Le TP, Wu P, Lainé M, Greene GL. RAC3 is a pro-migratory co-activator of ERa. Oncogene. 2011 Apr 28; 30(17):1984-94. View in: PubMed

  46. Sinkevicius KW, Woloszyn K, Laine M, Jackson KS, Greene GL, Woodruff TK, Burdette JE. Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor alpha knock-in (ENERKI) mice. Steroids. 2009 Nov; 74(12):913-9. View in: PubMed

  47. Sinkevicius KW, Laine M, Lotan TL, Woloszyn K, Richburg JH, Greene GL. Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility. Endocrinology. 2009 Jun; 150(6):2898-905. View in: PubMed

  48. Haiman CA, Garcia RR, Hsu C, Xia L, Ha H, Sheng X, Le Marchand L, Kolonel LN, Henderson BE, Stallcup MR, Greene GL, Press MF. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer. 2009 Jan 30; 9:43. View in: PubMed

  49. Leong H, Mathur PS, Greene GL. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat. 2009 Oct; 117(3):505-15. View in: PubMed

  50. O'Neill EE, Blewett AR, Loria PM, Greene GL. Modulation of alphaCaMKII signaling by rapid ERalpha action. Brain Res. 2008 Jul 30; 1222:1-17. View in: PubMed

  51. Nettles KW, Bruning JB, Gil G, Nowak J, Sharma SK, Hahm JB, Kulp K, Hochberg RB, Zhou H, Katzenellenbogen JA, Katzenellenbogen BS, Kim Y, Joachmiak A, Greene GL. NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol. 2008 Apr; 4(4):241-7. View in: PubMed

  52. Sinkevicius KW, Burdette JE, Woloszyn K, Hewitt SC, Hamilton K, Sugg SL, Temple KA, Wondisford FE, Korach KS, Woodruff TK, Greene GL. An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008 Jun; 149(6):2970-9. View in: PubMed

  53. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. Steroids. 2008 Jan; 73(1):59-68. View in: PubMed

  54. Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB, Greene GL. CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol. 2008 Feb; 22(2):263-72. View in: PubMed

  55. Zhou HB, Nettles KW, Bruning JB, Kim Y, Joachimiak A, Sharma S, Carlson KE, Stossi F, Katzenellenbogen BS, Greene GL, Katzenellenbogen JA. Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol. 2007 Jun; 14(6):659-69. View in: PubMed

  56. Leong H, Mathur PS, Greene GL. Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat. 2008 Feb; 107(3):359-69. View in: PubMed

  57. Nettles KW, Bruning JB, Gil G, O'Neill EE, Nowak J, Guo Y, Hughs A, Kim Y, DeSombre ER, Dilis R, Hanson RN, Joachimiak A, Greene GL. Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep. 2007 Jun; 8(6):563-8. View in: PubMed

  58. Zhou HB, Sheng S, Compton DR, Kim Y, Joachimiak A, Sharma S, Carlson KE, Katzenellenbogen BS, Nettles KW, Greene GL, Katzenellenbogen JA. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem. 2007 Jan 25; 50(2):399-403. View in: PubMed

  59. Blissmer B, Riebe D, Dye G, Ruggiero L, Greene G, Caldwell M. Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: intervention and 24 month follow-up effects. Health Qual Life Outcomes. 2006 Jul 17; 4:43. View in: PubMed

  60. Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, Greene GL. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem. 2006 Jun 30; 281(26):17909-19. View in: PubMed

  61. Huang J, Koide A, Nettle KW, Greene GL, Koide S. Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor. Protein Expr Purif. 2006 Jun; 47(2):348-54. View in: PubMed

  62. Yeo WS, Min DH, Hsieh RW, Greene GL, Mrksich M. Label-free detection of protein-protein interactions on biochips. Angew Chem Int Ed Engl. 2005 Aug 26; 44(34):5480-3. View in: PubMed

  63. Leong H, Sloan JR, Nash PD, Greene GL. Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol. 2005 Dec; 19(12):2930-42. View in: PubMed

  64. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell. 2005 May 13; 18(4):413-24. View in: PubMed

  65. Nettles KW, Greene GL. Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol. 2005; 67:309-33. View in: PubMed

  66. Greene GL, Shiau AK, Nettles KW. A structural explanation for ERalpha/ERbeta SERM discrimination. Ernst Schering Res Found Workshop. 2004; (46):33-45. View in: PubMed

  67. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004 Dec; 18(12):2854-65. View in: PubMed

  68. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez AL, Katzenellenbogen JA, Katzenellenbogen BS, Greene GL. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell. 2004 Feb 13; 13(3):317-27. View in: PubMed

  69. Nettles KW, Greene GL. Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"? Mol Cell. 2003 Apr; 11(4):850-1. View in: PubMed

  70. Benz C, Clark G, Conzen S, Dorn R, Fuqua S, Gralow J, Greene G, Heimann R, Hellman S, Lippman M, Rosen N, Weiner L. Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat. 2003 Mar; 78(1):127-31. View in: PubMed

  71. Greene GL. In vivo imaging reveals estrogen receptor's hidden personality. Nat Med. 2003 Jan; 9(1):22-3. View in: PubMed

  72. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. 2002 May; 9(5):359-64. View in: PubMed

  73. Janulis M, Trakul N, Greene G, Schaefer EM, Lee JD, Rosner MR. A novel mitogen-activated protein kinase is responsive to Raf and mediates growth factor specificity. Mol Cell Biol. 2001 Mar; 21(6):2235-47. View in: PubMed

  74. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000 Nov 30; 74(5):311-7. View in: PubMed

  75. Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P, Greene G. Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp. 2000; 230:20-6; discussion 27-40. View in: PubMed

  76. Mungall WS, Greene GL, Miller PS, Letsinger RL. Use of phosphorus oxychloride in synthesizing nucleotides and oligonucleotides. Nucleic Acids Res. 1974 Apr; 1(4):615-27. View in: PubMed

  77. Li G, Chen YF, Greene GL, Oparil S, Thompson JA. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation. 1999 Oct 12; 100(15):1639-45. View in: PubMed

  78. Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, Kushner PJ. Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol Endocrinol. 1999 Jun; 13(6):897-909. View in: PubMed

  79. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999 Feb; 13(2):307-19. View in: PubMed

  80. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23; 95(7):927-37. View in: PubMed

  81. Greene ME, Blumberg B, Kwan K, Hsieh L, Greene GL, Nimer SD. Isolation and cloning of human peroxisome proliferator activated receptor gamma cDNA. Adv Exp Med Biol. 1997; 400A:253-60. View in: PubMed

  82. Wood JR, Greene GL, Nardulli AM. Estrogen response elements function as allosteric modulators of estrogen receptor conformation. Mol Cell Biol. 1998 Apr; 18(4):1927-34. View in: PubMed

  83. Landel CC, Potthoff SJ, Nardulli AM, Kushner PJ, Greene GL. Estrogen receptor accessory proteins augment receptor-DNA interaction and DNA bending. J Steroid Biochem Mol Biol. 1997 Sep-Oct; 63(1-3):59-73. View in: PubMed

  84. Hess RA, Gist DH, Bunick D, Lubahn DB, Farrell A, Bahr J, Cooke PS, Greene GL. Estrogen receptor (alpha and beta) expression in the excurrent ducts of the adult male rat reproductive tract. J Androl. 1997 Nov-Dec; 18(6):602-11. View in: PubMed

  85. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16; 389(6652):753-8. View in: PubMed

  86. DeSombre ER, Hughes A, Landel CC, Greene G, Hanson R, Schwartz JL. Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. Acta Oncol. 1996; 35(7):833-40. View in: PubMed

  87. Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GL. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996 Oct; 63(1):28-33. View in: PubMed

  88. Greene GJ, Jensen C, Harper Jones D. A constructivist perspective on clinical social work practice with ethnically diverse clients. Soc Work. 1996 Mar; 41(2):172-80. View in: PubMed

  89. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, Schnaper HW. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation. 1996 Sep 15; 94(6):1402-7. View in: PubMed

  90. Nardulli AM, Romine LE, Carpo C, Greene GL, Rainish B. Estrogen receptor affinity and location of consensus and imperfect estrogen response elements influence transcription activation of simplified promoters. Mol Endocrinol. 1996 Jun; 10(6):694-704. View in: PubMed

  91. Landel CC, Kushner PJ, Greene GL. Estrogen receptor accessory proteins: effects on receptor-DNA interactions. Environ Health Perspect. 1995 Oct; 103 Suppl 7:23-8. View in: PubMed

  92. Seielstad DA, Carlson KE, Katzenellenbogen JA, Kushner PJ, Greene GL. Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. Mol Endocrinol. 1995 Jun; 9(6):647-58. View in: PubMed

  93. Miller RT, Hapke MR, Greene GL. Immunocytochemical assay for estrogen receptor with monoclonal antibody D753P gamma in routinely processed formaldehyde-fixed breast tissue. Comparison with frozen section assay and with monoclonal antibody H222. Cancer. 1993 Jun 01; 71(11):3541-6. View in: PubMed

  94. Nardulli AM, Greene GL, Shapiro DJ. Human estrogen receptor bound to an estrogen response element bends DNA. Mol Endocrinol. 1993 Mar; 7(3):331-40. View in: PubMed

  95. Tucker MS, Khan I, Fuchs-Young R, Price S, Steininger TL, Greene G, Wainer BH, Rosner MR. Localization of immunoreactive epidermal growth factor receptor in neonatal and adult rat hippocampus. Brain Res. 1993 Dec 17; 631(1):65-71. View in: PubMed

  96. Fuqua SA, Allred DC, Elledge RM, Krieg SL, Benedix MG, Nawaz Z, O'Malley BW, Greene GL, McGuire WL. The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202. View in: PubMed

  97. Landel CC, Kushner PJ, Greene GL. The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol. 1994 Oct; 8(10):1407-19. View in: PubMed

  98. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995; 4(4-5):281-99. View in: PubMed

  99. Nyholm HC, Nielsen AL, Lyndrup J, Greene GL, Thorpe SM. Estrogen receptor determination in endometrial carcinoma: ligand binding assay versus enzyme immunoassay. Anticancer Res. 1995 Mar-Apr; 15(2):649-54. View in: PubMed

  100. Seielstad DA, Carlson KE, Kushner PJ, Greene GL, Katzenellenbogen JA. Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry. 1995 Oct 03; 34(39):12605-15. View in: PubMed

  101. Pertschuk LP, Macchia RJ, Feldman JG, Brady KA, Levine M, Kim DS, Eisenberg KB, Rainford E, Prins GS, Greene GL. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Ann Surg Oncol. 1994 Nov; 1(6):495-503. View in: PubMed

  102. Greene GL, Closs LE, De Sombre ER, Jensen EV. Estrophilin: pro and anti. J Steroid Biochem. 1980 Jan; 12:159-67. View in: PubMed

  103. Garcia M, Greene G, Rochefort H, Jensen EV. Effect of antibodies to estrogen receptor on the binding of 3H-labeled antiestrogens and androstanediol in the uterus. Endocrinology. 1982 Apr; 110(4):1355-61. View in: PubMed

  104. Greene GL, Nolan C, Engler JP, Jensen EV. Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci U S A. 1980 Sep; 77(9):5115-9. View in: PubMed

  105. Greene GL, Jensen EV. Monoclonal antibodies as probes for estrogen receptor detection and characterization. J Steroid Biochem. 1982 Mar; 16(3):353-9. View in: PubMed

  106. Greene GL, Fitch FW, Jensen EV. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc Natl Acad Sci U S A. 1980 Jan; 77(1):157-61. View in: PubMed

  107. Giambiagi N, Pasqualini JR, Greene G, Jensen EV. Recognition of two forms of the estrogen receptor in the guinea-pig uterus at different stages of development by a monoclonal antibody to the human estrogen receptor. Dynamics of the translocation of these two forms to the nucleus. J Steroid Biochem. 1984 Jan; 20(1):397-400. View in: PubMed

  108. King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 1984 Feb 23-29; 307(5953):745-7. View in: PubMed

  109. Tate AC, Greene GL, DeSombre ER, Jensen EV, Jordan VC. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res. 1984 Mar; 44(3):1012-8. View in: PubMed

  110. Miller MA, Greene GL, Katzenellenbogen BS. Estrogen receptor transformation in MCF-7 breast cancer cells: characterization by immunochemical and sedimentation analyses. Endocrinology. 1984 Jan; 114(1):296-8. View in: PubMed

  111. Tate AC, DeSombre ER, Greene GL, Jensen EV, Jordan VC. Interaction of [3H] estradiol - and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Res Treat. 1983; 3(3):267-77. View in: PubMed

  112. DeSombre ER, Greene GL, King WJ, Jensen EV. Estrogen receptors, antibodies and hormone dependent cancer. Prog Clin Biol Res. 1984; 142:1-21. View in: PubMed

  113. Kasid A, Strobl JS, Huff K, Greene GL, Lippman ME. A novel nuclear form of estradiol receptor in MCF-7 human breast cancer cells. Science. 1984 Sep 14; 225(4667):1162-5. View in: PubMed

  114. Press MF, Nousek-Goebl N, King WJ, Herbst AL, Greene GL. Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. Lab Invest. 1984 Nov; 51(5):495-503. View in: PubMed

  115. McClellan MC, West NB, Tacha DE, Greene GL, Brenner RM. Immunocytochemical localization of estrogen receptors in the macaque reproductive tract with monoclonal antiestrophilins. Endocrinology. 1984 Jun; 114(6):2002-14. View in: PubMed

  116. Press MF, Greene GL. An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab Invest. 1984 Apr; 50(4):480-6. View in: PubMed

  117. Jensen EV, Greene GL, Closs LE, DeSombre ER, Nadji M. Receptors reconsidered: a 20-year perspective. Recent Prog Horm Res. 1982; 38:1-40. View in: PubMed

  118. Venter JC, Berzofsky JA, Lindstrom J, Jacobs S, Fraser CM, Kohn LD, Schneider WJ, Greene GL, Strosberg AD, Erlanger BF. Monoclonal and anti-idiotypic antibodies as probes for receptor structure and function. Fed Proc. 1984 Jul; 43(10):2532-9. View in: PubMed

  119. Greene GL, Sobel NB, King WJ, Jensen EV. Immunochemical studies of estrogen receptors. J Steroid Biochem. 1984 Jan; 20(1):51-6. View in: PubMed

  120. Ekman P, Barrack ER, Greene GL, Jensen EV, Walsh PC. Estrogen receptors in human prostate: evidence for multiple binding sites. J Clin Endocrinol Metab. 1983 Jul; 57(1):166-76. View in: PubMed

  121. Press MF, Holt JA, Herbst AL, Greene GL. Immunocytochemical identification of estrogen receptor in ovarian carcinomas. Localization with monoclonal estrophilin antibodies compared with biochemical assays. Lab Invest. 1985 Sep; 53(3):349-61. View in: PubMed

  122. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology. 1985 Oct; 117(4):1409-17. View in: PubMed

  123. Press MF, Nousek-Goebl NA, Greene GL. Immunoelectron microscopic localization of estrogen receptor with monoclonal estrophilin antibodies. J Histochem Cytochem. 1985 Sep; 33(9):915-24. View in: PubMed

  124. Lorincz MA, Holt JA, Greene GL. Monoclonal antibody recognition of multiple forms of estrogen receptor tagged with [125I]methoxy-iodovinyl estradiol in ovarian carcinomas. J Clin Endocrinol Metab. 1985 Sep; 61(3):412-7. View in: PubMed

  125. Miller MA, Mullick A, Greene GL, Katzenellenbogen BS. Characterization of the subunit nature of nuclear estrogen receptors by chemical cross-linking and dense amino acid labeling. Endocrinology. 1985 Aug; 117(2):515-22. View in: PubMed

  126. Kodama F, Greene GL, Salmon SE. Relation of estrogen receptor expression to clonal growth and antiestrogen effects on human breast cancer cells. Cancer Res. 1985 Jun; 45(6):2720-4. View in: PubMed

  127. King WJ, DeSombre ER, Jensen EV, Greene GL. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res. 1985 Jan; 45(1):293-304. View in: PubMed

  128. Mundy EA, Neiders ME, Sako K, Greene GW. Maxillary sinus cancer: a study of 33 cases. J Oral Pathol. 1985 Jan; 14(1):27-36. View in: PubMed

  129. Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A. 1985 Dec; 82(23):7889-93. View in: PubMed

  130. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986 Mar 07; 231(4742):1150-4. View in: PubMed

  131. Denner LA, Bingman WE, Greene GL, Weigel NL. Phosphorylation of the chicken progesterone receptor. J Steroid Biochem. 1987; 27(1-3):235-43. View in: PubMed

  132. Katzenellenbogen BS, Elliston JF, Monsma FJ, Springer PA, Ziegler YS, Greene GL. Structural analysis of covalently labeled estrogen receptors by limited proteolysis and monoclonal antibody reactivity. Biochemistry. 1987 Apr 21; 26(8):2364-73. View in: PubMed

  133. Alexander RB, Greene GL, Barrack ER. Estrogen receptors in the nuclear matrix: direct demonstration using monoclonal antireceptor antibody. Endocrinology. 1987 May; 120(5):1851-7. View in: PubMed

  134. Greene GL, Press MF. Structure and dynamics of the estrogen receptor. J Steroid Biochem. 1986 Jan; 24(1):1-7. View in: PubMed

  135. Rao KV, Peralta WD, Greene GL, Fox CF. Cellular progesterone receptor phosphorylation in response to ligands activating protein kinases. Biochem Biophys Res Commun. 1987 Aug 14; 146(3):1357-65. View in: PubMed

  136. Law ML, Kao FT, Wei Q, Hartz JA, Greene GL, Zarucki-Schulz T, Conneely OM, Jones C, Puck TT, O'Malley BW, et al. The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proc Natl Acad Sci U S A. 1987 May; 84(9):2877-81. View in: PubMed

  137. Ingegno MD, Money SR, Thelmo W, Greene GL, Davidian M, Jaffe BM, Pertschuk LP. Progesterone receptors in the human heart and great vessels. Lab Invest. 1988 Sep; 59(3):353-6. View in: PubMed

  138. Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol. 1988 Mar; 2(3):263-71. View in: PubMed

  139. Waterman ML, Adler S, Nelson C, Greene GL, Evans RM, Rosenfeld MG. A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. Mol Endocrinol. 1988 Jan; 2(1):14-21. View in: PubMed

  140. Nardulli AM, Greene GL, O'Malley BW, Katzenellenbogen BS. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology. 1988 Mar; 122(3):935-44. View in: PubMed

  141. Press MF, Greene GL. Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology. 1988 Mar; 122(3):1165-75. View in: PubMed

  142. Bur ME, Greene GL, Press MF. Estrogen receptor localization in formalin-fixed, paraffin-embedded endometrium and endometriotic tissues. Int J Gynecol Pathol. 1987; 6(2):140-51. View in: PubMed

  143. Jensen EV, Greene GL, DeSombre ER. Immunochemical studies of estrogen receptors. Prog Clin Biol Res. 1987; 249:283-305. View in: PubMed

  144. Press MF, Udove JA, Greene GL. Progesterone receptor distribution in the human endometrium. Analysis using monoclonal antibodies to the human progesterone receptor. Am J Pathol. 1988 Apr; 131(1):112-24. View in: PubMed

  145. West NB, Roselli CE, Resko JA, Greene GL, Brenner RM. Estrogen and progestin receptors and aromatase activity in rhesus monkey prostate. Endocrinology. 1988 Nov; 123(5):2312-22. View in: PubMed

  146. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988 Jul 01; 241(4861):81-4. View in: PubMed

  147. Greene GL. Estrogen and progesterone receptor measurements with monoclonal antibodies. Int J Biol Markers. 1988 Jan-Mar; 3(1):57-9. View in: PubMed

  148. Raymoure WJ, McNaught RW, Greene GL, Smith RG. Receptor interconversion model of hormone action. II. Nucleotide-mediated conversion of estrogen receptors from nonsteroid binding to the lower affinity binding state. J Biol Chem. 1986 Dec 25; 261(36):17018-25. View in: PubMed

  149. Press MF, Nousek-Goebl NA, Bur M, Greene GL. Estrogen receptor localization in the female genital tract. Am J Pathol. 1986 May; 123(2):280-92. View in: PubMed

  150. Klein-Hitpass L, Tsai SY, Greene GL, Clark JH, Tsai MJ, O'Malley BW. Specific binding of estrogen receptor to the estrogen response element. Mol Cell Biol. 1989 Jan; 9(1):43-9. View in: PubMed

  151. Maxwell BL, McDonnell DP, Conneely OM, Schulz TZ, Greene GL, O'Malley BW. Structural organization and regulation of the chicken estrogen receptor. Mol Endocrinol. 1987 Jan; 1(1):25-35. View in: PubMed

  152. De Rosa CM, Ozzello L, Greene GL, Habif DV. Immunostaining of estrogen receptor in paraffin sections of breast carcinomas using monoclonal antibody D75P3 gamma: effects of fixation. Am J Surg Pathol. 1987 Dec; 11(12):943-50. View in: PubMed

  153. Harlow KW, Smith DN, Katzenellenbogen JA, Greene GL, Katzenellenbogen BS. Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J Biol Chem. 1989 Oct 15; 264(29):17476-85. View in: PubMed

  154. Read LD, Greene GL, Katzenellenbogen BS. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol. 1989 Feb; 3(2):295-304. View in: PubMed

  155. Berger U, Wilson P, Thethi S, McClelland RA, Greene GL, Coombes RC. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res. 1989 Sep 15; 49(18):5176-9. View in: PubMed

  156. Press MF, Xu SH, Wang JD, Greene GL. Subcellular distribution of estrogen receptor and progesterone receptor with and without specific ligand. Am J Pathol. 1989 Nov; 135(5):857-64. View in: PubMed

  157. Brustein S, Fruchter R, Greene GL, Pertschuk LP. Immunocytochemical assay of progesterone receptors in paraffin-embedded specimens of endometrial carcinoma and hyperplasia: a preliminary evaluation. Mod Pathol. 1989 Sep; 2(5):449-55. View in: PubMed

  158. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989 Feb 15; 49(4):1052-6. View in: PubMed

  159. Poulsen HS, Ozzello L, King WJ, Greene GL. The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue. J Histochem Cytochem. 1985 Feb; 33(2):87-92. View in: PubMed

  160. Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989 Jan 01; 49(1):145-8. View in: PubMed

  161. DeRosa CM, Ozzello L, Habif DV, Konrath JG, Greene GL. Immunohistochemical assessment of estrogen and progesterone receptors in stored imprints and cryostat sections of breast carcinomas. Ann Surg. 1989 Aug; 210(2):224-8. View in: PubMed

  162. DonCarlos LL, Greene GL, Morrell JI. Estrogen plus progesterone increases progestin receptor immunoreactivity in the brain of ovariectomized guinea pigs. Neuroendocrinology. 1989 Dec; 50(6):613-23. View in: PubMed

  163. Greene GL, Harris K, Bova R, Kinders R, Moore B, Nolan C. Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies. Mol Endocrinol. 1988 Aug; 2(8):714-26. View in: PubMed

  164. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab. 1988 Aug; 67(2):334-40. View in: PubMed

  165. Conneely OM, Sullivan WP, Toft DO, Birnbaumer M, Cook RG, Maxwell BL, Zarucki-Schulz T, Greene GL, Schrader WT, O'Malley BW. Molecular cloning of the chicken progesterone receptor. Science. 1986 Aug 15; 233(4765):767-70. View in: PubMed

  166. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem. 1986 Jan; 24(1):77-83. View in: PubMed

  167. Lozowski M, Greene GL, Sadri D, Stanick D, Pai P, Harris MA, Lundy J. The use of fine needle aspirates in the evaluation of progesterone receptor content in breast cancer. Acta Cytol. 1990 Jan-Feb; 34(1):27-30. View in: PubMed

  168. Falette NS, Fuqua SA, Chamness GC, Cheah MS, Greene GL, McGuire WL. Estrogen receptor gene methylation in human breast tumors. Cancer Res. 1990 Jul 01; 50(13):3974-8. View in: PubMed

  169. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer. 1990 Oct 15; 66(8):1663-70. View in: PubMed

  170. Kushner PJ, Hort E, Shine J, Baxter JD, Greene GL. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol Endocrinol. 1990 Oct; 4(10):1465-73. View in: PubMed

  171. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology. 1991 Dec; 129(6):3187-99. View in: PubMed

  172. Tóth J, De Sombre ER, Greene GL. Immunohistochemical analysis of estrogen and progesterone receptors in benign breast diseases. Zentralbl Pathol. 1991; 137(3):227-32. View in: PubMed

  173. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991 Jan 01; 51(1):239-44. View in: PubMed

  174. Ozzello L, DeRosa C, Habif DV, Greene GL. An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer. 1991 Jan 15; 67(2):455-62. View in: PubMed

  175. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6. View in: PubMed

  176. Fuqua SA, Hill SM, Chamness GC, Benedix MG, Greene GL, O'Malley BW, McGuire WL. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst. 1991 Aug 21; 83(16):1157-60. View in: PubMed

  177. Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ. The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol. 1992 Feb; 6(2):157-67. View in: PubMed

  178. Jung-Testas I, Renoir M, Bugnard H, Greene GL, Baulieu EE. Demonstration of steroid hormone receptors and steroid action in primary cultures of rat glial cells. J Steroid Biochem Mol Biol. 1992 Mar; 41(3-8):621-31. View in: PubMed

  179. Wang JD, Fu Y, Shi WL, Zhu PD, Cheng J, Qiao GM, Wang YQ, Greene GL. Immunohistochemical localization of progesterone receptor in human decidua of early pregnancy. Hum Reprod. 1992 Jan; 7(1):123-7. View in: PubMed

  180. Bettuzzi S, Robinson A, Fuchs-Young R, Greene GL. Estrogen and progesterone receptor structure and action in breast cancer cells. Cancer Treat Res. 1992; 61:301-15. View in: PubMed

  181. Beckmann MW, Toney LJ, Scharl A, Fuchs-Young R, Greene GL, Holt JA. Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays. Eur J Cancer. 1992; 28(2-3):322-6. View in: PubMed

  182. Greene GL, Letsinger RL. Formation of internucleotide 3'-5' phosphoramidate links by direct coupling of phosphoryl and amino groups. Nucleic Acids Res. 1975 Jul; 2(7):1123-7. View in: PubMed

  183. Mungall WS, Greene GL, Heavner GA, Letsinger RL. Use of azido group in the synthesis of 5' terminal aminodeoxythymidine oligonucleotides. J Org Chem. 1975 May 30; 40(11):1569-62. View in: PubMed

  184. Greene GL, Closs LE, DeSombre ER, Jensen EV. Antibodies to estrophilin: comparison between rabbit and goat antisera. J Steroid Biochem. 1979 Jul; 11(1A):333-41. View in: PubMed

  185. Jensen EV, Greene GL, Closs LE, DeSombre ER. The immunoendocrinology of estrophilin. Adv Exp Med Biol. 1979; 117:1-16. View in: PubMed

  186. Ballard BR, Suess GR, Pickren JW, Greene GW, Shedd DP. Squamous-cell carcinoma of the floor of the mouth. Oral Surg Oral Med Oral Pathol. 1978 Apr; 45(4):568-79. View in: PubMed

  187. Greene GL, Closs LE, Fleming H, DeSombre ER, Jensen EV. Antibodies to estrogen receptor: immunochemical similarity of estrophilin from various mammalian species. Proc Natl Acad Sci U S A. 1977 Sep; 74(9):3681-5. View in: PubMed